U.S. flag An official website of the United States government
  1. Home
  2. Drugs
  3. News & Events for Human Drugs
  4. Assessing Changes in Pharmacokinetics of Drugs in Liver Disease - 10/08/2020 - 10/08/2020
  1. News & Events for Human Drugs

Public

Event Title
Assessing Changes in Pharmacokinetics of Drugs in Liver Disease
October 8, 2020


Date:
October 8, 2020
Time:
10:00 AM - 4:00 PM ET

The U.S. Food and Drug Administration (FDA), in collaboration with the University of Maryland Center of Excellence in Regulatory Science and Innovation (M-CERSI), will host a virtual public workshop entitled “Assessing Changes in Pharmacokinetics of Drugs in Liver Disease” on October 8, 2020. This workshop will bring together stakeholders from FDA, academia, and industry in a virtual setting to discuss advances to improve assessing the impact of hepatic function on the pharmacokinetics of a drug.

Drug development for a target population includes patients with various comorbidities, including liver disease. Patients with liver disease can have a decreased capacity to eliminate drugs via the liver and may require dosage adjustments. Dosage adjustment is typically based on bridging pharmacokinetic parameters between a population with impaired hepatic function to a population with normal hepatic function. This requires reliable biomarkers that identify and classify the underlying impairment in hepatic function by reflecting the trajectory of changes in biotransformation capacity due to liver disease. While current FDA guidance has been the standard for evaluating the impact of impaired hepatic function on the pharmacokinetics of new drugs, challenges in implementation include difficulties in enrolling patients, delays in hepatic impairment studies until late in the drug development, and the fact that current markers of hepatic function are more relevant for patients with cirrhosis.

Key topics of discussion include novel research on:

  • Relevant biomarkers and their predictive ability to identify changes in biotransformation and transport capacity of the liver
  • Classification of degree of impairment in biotransformation and transport capacity of the diseased liver
  • Potential differences in pharmacokinetics in different underlying liver diseases
  • The role of PBPK in characterizing the PK of drugs in hepatic impairment

Meeting Information and Registration:

This workshop is open to the public with no cost to attend, but registration is required. For more information, visit the University of Maryland Center of Excellence in Regulatory Science and Innovation (M-CERSI) website. 

To register, visit the M-CERSI registration form.

Questions:

For questions regarding this event, please contact:

Martina Sahre
Office of Clinical Pharmacology
Center for Drug Evaluation and Research
U.S. Food and Drug Administration
Phone: 301-796-9659
Email:
martina.sahre@fda.hhs.gov

Back to Top